TP53 and neoplasm: There is evidence that reduced TCR capacity increases the susceptibility of tumor cells to apoptosis induced by cisplatin even in cell lines with p53 mutation and DNA mismatch defects, and that the TCR system may be a potential target in overcoming cisplatin resistance in cancer treatment (97).